ARCHIVES

Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs

This article is from The Cancer Letter archive.

Vol. 16 No. 34 | September 7, 1990

Download PDF Visit The Full Archive

Related Articles

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987

Et2’s Referral Guidelines

July 23, 1993

Broder Encourages Support Of Drug Development Programs

March 10, 1995

Shortage Of Patients In Right Place, Time Develops As Major Problem For Investigators

May 3, 1974

NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan.

March 11, 2005

Clinical Trials Streamlining Moves Forward; NCI Commits To Full Funding For Groups

October 9, 1998